321747-01-7

Upstream product

• 295-37-4 1,4,8,11-Tetraazacyclotetradecane 
• 24424-99-5 di-tert-butyl dicarbonate 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 170161-27-0 1,4,8-tris(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 

Downstream Products

• 164794-97-2 N-Boc protected 4-<(1,4,8,11-tetraazacyclotetradec-1-yl)methyl>benzoic acid 
• 1254176-45-8 C₁₈H₃₀N₄O 
• 1242274-98-1 1-[4-(carboxaldehyde)phenylmethyl]-4,8,11-tris-(tert-butoxycarbonyl)-1,4,8,11-tetraazacyclotetradecane 
• 1254176-47-0 C₅₆H₈₈N₆O₁₅ 
• 1254176-43-6 C₃₃H₅₆N₄O₇ 

Relevant academic research and scientific papers

β-amyloid peptide inhibitors

The present invention relates to compounds which inhibit the binding of metal ions to a region in the N-terminal loop of the β-amyloid peptide which includes a cluster of histidine residues. In addition, the invention relates to pharmaceutical composition

HETEROBIFUNCTIONAL INHIBITORS OF E-SELECTINS AND CXCR4 CHEMOKINE RECEPTORS

Compounds, compositions and methods are provided for treating cancer and inflammatory diseases, and for releasing cells such as stem cells (e.g., bone marrow progenitor cells) into circulating blood and enhancing retention of the cells in the blood. More specifically, heterobifunctional compounds that inhibit both E-selectins and CXCR4 chemokine receptors are described.